Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Growth Metrics

Others

ProPhase Labs (PRPH) Notes Payables (2024 - 2025)

Historic Notes Payables for ProPhase Labs (PRPH) over the last 2 years, with Q3 2025 value amounting to $3.2 million.

ProPhase Labs' Notes Payables rose 1928.84% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 1928.84%. This contributed to the annual value of $3.2 million for FY2024, which is N/A changed from last year.
Per ProPhase Labs' latest filing, its Notes Payables stood at $3.2 million for Q3 2025, which was up 1928.84% from $2.4 million recorded in Q2 2025.
In the past 5 years, ProPhase Labs' Notes Payables registered a high of $3.3 million during Q2 2024, and its lowest value of $2.4 million during Q1 2024.